Merck Initiates Gardasil Detailing; Campaign To Focus On Cancer Prevention
Executive Summary
Merck has begun detailing its pending human papilloma virus vaccine Gardasil to non-routine vaccinators, the company reported Dec. 15 during an annual business review in Whitehouse Station, N.J
You may also be interested in...
Gardasil Clears FDA, But Dosing May Pose Administrative Challenges
Administration of Merck's recently approved human papillomavirus vaccine Gardasil at the recommended schedule of zero, two and six months may pose a logistical challenge to vaccinating adolescents
Gardasil Clears FDA, But Dosing May Pose Administrative Challenges
Administration of Merck's recently approved human papillomavirus vaccine Gardasil at the recommended schedule of zero, two and six months may pose a logistical challenge to vaccinating adolescents
Merck Seeks Early Gardasil Male Recommendation, But FDA, CDC Are Wary
Merck's presentation of data on the use of Gardasil in males at FDA's recent Vaccines & Related Biological Products Advisory Committee meeting suggests the firm is positioning the product for a broader recommendation from the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices